Skip NavigationSkip to Content
Return Return to Search Results

Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells

  1. Author:
    Reshma, R. S.
    Sreelatha, K. H.
    Somasundaram, V.
    Satheesh Kumar, S.
    Nadhan, R.
    Nair, R. S.
    Srinivas, P.

  2. Author Address

    Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India.;Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India; Center for Cancer Research, National Cancer Institute, Building 567, Room 254, Frederick, MD 21702-1201, United States.;Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India; Dep. of Surgery, Post Doctoral Research Associate, University of Illinois at Chicago, School of Medicine, 840 South Wood Street, Chicago, IL 60612, United States.;Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India. Electronic address: priyasrinivas@rgcb.res.in.
    1. Year: 2016
    2. Date: Mar
    3. Epub Date: 1/26/2016
  2. Journal: Pharmacological Research
    1. 105
    2. Pages: 134-45
  4. Type of Article: Article
  5. ISSN: 1043-6618
  1. Abstract:

    Eventhough the role of BRCA1/2 in hereditary prostatic cancer is being unleashed at a rapid rate; their optimal clinical management remains undefined. Cancer stem cells are thought to be responsible for cancer chemoresistance and relapse, thus they represent a significant concern for cancer prognosis and therapy. In this study, we have analyzed the effect of Plumbagin (PB) and structurally related naphthaquinones on BRCA1/2 silenced prostate cancer cells and the ability of PB to target stem cells. Our cell proliferation studies showed that both PC-3 and DU145 cells were more sensitive to PB, though all the compounds induced mitochondrial potential loss, DNA fragmentation and morphological changes which are indicative of apoptosis. Both BRCA1/2 siRNA transfected PC-3 and DU145 cells exhibited increased sensitivity to PB. Gene expression profiling post PB treatment in BRCA1/2 silenced cells revealed that PB has a putative role in tumor suppression in BRCA defective cancers. Using flow cytometric analysis we have proved that PB has the putative ability to directly target CSCs. Overall studies suggest that PB's antitumour mechanisms holds promise for novel therapeutic approaches against BRCA mutated cancers as well as CSCs.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.phrs.2016.01.012
  3. PMID: 26808083

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel